Litcius/Paper detail

The role of peroxisome proliferator‐activated receptors in the regulation of bile acid metabolism

Yuqing Sun, Luyong Zhang, Zhenzhou Jiang

2023Basic & Clinical Pharmacology & Toxicology24 citationsDOIOpen Access PDF

Abstract

Bile acids are synthesized from cholesterol in the liver. Dysregulation of bile acid homeostasis, characterized by excessive accumulation in the liver, gallbladder and blood, can lead to hepatocellular damage and the development of cholestatic liver disease. Nuclear receptors play a crucial role in the control of bile acid metabolism by efficiently regulating bile acid synthesis and transport in the liver. Among these receptors, peroxisome proliferator-activated receptor (PPAR), a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily, controls the expression of genes involved in adipogenesis, lipid metabolism, inflammation and glucose homeostasis and has emerged as a potential therapeutic target for the treatment of the metabolic syndrome in the past two decades. Emerging evidence suggests that PPAR activation holds promise as a therapeutic target for cholestatic liver disease, as it affects both bile acid production and transport. This review provides a comprehensive overview of recent advances in elucidating the role of PPAR in the regulation of bile acid metabolism, highlighting the current position of PPAR agonists in the treatment of primary biliary cholangitis. By summarizing the specific regulatory effects of PPAR on bile acids, this review contributes to the exploration of novel therapeutic strategies for cholestatic liver diseases.

Topics & Concepts

Nuclear receptorBile acidPeroxisome proliferator-activated receptorPeroxisomeFarnesoid X receptorLipid metabolismCYP8B1ReceptorLiver X receptorG protein-coupled bile acid receptorBiologyGlucose homeostasisMetabolismHomeostasisTranscription factorInternal medicineEndocrinologyBiochemistryMedicineInsulin resistanceDiabetes mellitusGeneDrug Transport and Resistance MechanismsPediatric Hepatobiliary Diseases and TreatmentsPeroxisome Proliferator-Activated Receptors